AWM Investment Company’s DiaMedica Therapeutics DMAC Stock Holding History

AWM Investment Company’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Hold	36,000	–	–	0.02%	106
2026 Q1	$244K	Buy	+36,000	New	+$285K	0.03%	98

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AWM Investment Company's DMAC Position: Q2 2026 in Review

AWM Investment Company held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 36,000 shares worth $253K. The position accounts for 0.02% of the portfolio, ranked #106.

AWM Investment Company first reported a position in DMAC in Q1 2026 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

AWM Investment Company held 36,000 shares of DiaMedica Therapeutics worth $253K as of Q2 2026.
AWM Investment Company left its DiaMedica Therapeutics share count unchanged in Q2 2026.
DiaMedica Therapeutics made up 0.02% of AWM Investment Company's portfolio in Q2 2026, its #106 holding.
AWM Investment Company first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 2 quarters since.
88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on AWM Investment Company's 13F filing for Q2 2026, filed 14 Aug 2026.